Portal de Periódicos da CAPES

A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins

2006; Elsevier BV; Volume: 345; Issue: 2 Linguagem: Inglês

10.1016/j.virol.2005.12.001

1096-0341

Peter J. Bredenbeek, Richard Molenkamp, Willy J. M. Spaan, Vincent Deubel, Phillippe Marianneau, María S. Salvato, Dmitry Moshkoff, Juan Carlos Zapata, Ilia Tikhonov, Jean L. Patterson, Ricardo Carrion, Anysha Ticer, Kathleen M. Brasky, Igor S. Lukashevich,

Hepatitis B Virus Studies

The Yellow Fever Vaccine 17D (YFV17D) has been used as a vector for the Lassa virus glycoprotein precursor (LASV-GPC) resulting in construction of YFV17D/LASV-GPC recombinant virus. The virus was replication-competent and processed the LASV-GPC in cell cultures. The recombinant replicated poorly in guinea pigs but still elicited specific antibodies against LASV and YFV17D antigens. A single subcutaneous injection of the recombinant vaccine protected strain 13 guinea pigs against fatal Lassa Fever. This study demonstrates the potential to develop an YFV17D-based bivalent vaccine against two viruses that are endemic in the same area of Africa.